Drug manufacturer Cipla has revealed that its Global CEO and Managing Director, Umang Vohra, will step down by the end of his term in March 2026, concluding nearly ten years in the top executive position, as per Reuters.
A leadership transition is underway at Cipla as the company announced that Achin Gupta, the current Global Chief Operating Officer (COO) at Cipla, will succeed Vohra as CEO and MD starting April 1, 2026, for a five-year tenure. Gupta, who joined Cipla in 2021, was promoted to the role of Global COO in February 2025.
Cipla clarified that this leadership shift is part of its pre-planned succession strategy and will be presented to shareholders for their endorsement.
In addition to the leadership changes, Cipla reported robust performance in the second quarter, surpassing expectations with a strong profit growth driven by consistent demand for its respiratory medications. The company’s consolidated net profit for the quarter concluding on September 30, 2025, stood at Rs 13.51 billion, marking a 3.7% increase from the previous year and slightly exceeding analyst projections of Rs 13.47 billion. Total revenue also saw a 7.6% rise to Rs 75.89 billion, outperforming anticipated figures of Rs 74.30 billion.
The Indian market played a significant role in Cipla’s growth, with revenue from India, its primary market, climbing by 7% to Rs 31.46 billion, primarily fueled by an 8% surge in respiratory drug sales. Meanwhile, North American sales totaled $233 million, slightly lower than the $237 million recorded a year earlier. Collectively, India and North America contributed to nearly three-fourths of Cipla’s total revenue.
In contrast, competitor Dr. Reddy’s Laboratories recently reported weaker financial results, falling short of profit expectations and experiencing a 13% drop in North American sales.